JP Morgan Raises PT On Genomic Health To $18

February 9, 2011 8:03 AM | 8 seconds read | Make a Comment

JP Morgan has raised the price target on Genomic Health, Inc.

GHDX

from $17 to $18 and maintains its Neutral rating.

Posted In: Price Target Analyst Ratings Biotechnology Genomic Health Health Care JP Morgan

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.